Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR Expressio
Phase 2
- Conditions
- Sarcoma with c-kit or PDGFR expression by immunohistochemistry
- Registration Number
- JPRN-C000000073
- Lead Sponsor
- Office of Imatinib phase2 study
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) controlable or active infection 2) pregnacy or lactation 3) brain metastasis with clinical symptom
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate in patients with Imatinib 600mg/day
- Secondary Outcome Measures
Name Time Method 1) Response rate in patients with Imatinib 800mg/day 2) Adverse events 3) Time to progression 4) To evaluate relationships between response and profile of gene expression 5) Pharmacokinetics in adolescence patients